Paying for prescription drugs in the new administration

2 March 2021 - In a national survey in January 2020 involving 1011 participants, the second-ranked domestic priority for members of ...

Read more →

Bladder cancer drug shortage resolved with Health Canada approval

24 February 2021 - Verity-BCG bladder cancer treatment available for Canadian patients in the spring. ...

Read more →

TGA reviewing COVID-19 tests to rule out issues diagnosing variants

24 February 2021 - Adjunct Professor John Skerritt has tasked the nation’s medical regulator with ensuring COVID-19 tests are successfully ...

Read more →

Tecartus recommended by NICE

24 February 2021 - Treatment with autologous anti-CD19-transduced CD3+ cells (brexucabtagene autoleucel) is recommended for use within the Cancer Drugs Fund ...

Read more →

NICE terminates appraisal of Novartis medicine

24 February 2021 - NICE had intended to appraise omalizumab for the treatment of patients with chronic rhinosinusitis with nasal ...

Read more →

Takeda’s drug for acute hereditary angioedema seizure to get larger benefits

24 February 2021 - Takeda Pharmaceutical Korea said that the Ministry of Health and Welfare would grant expanded reimbursement for ...

Read more →

Anti-cancer drugs Ninlaro, Lutathera to get insurance benefits from March

24 February 2021 - Takeda’s multiple myeloma treatment Ninlaro (ixazomib) and Novartis’ neuroendocrine tumour drug Lutathera (lutetium oxodotreotide) will get ...

Read more →

ViiV Healthcare submits supplemental new drug application to US FDA for expanded use of Cabenuva (cabotegravir, rilpivirine) as an HIV treatment for use every 2 months

24 February 2021 - ViiV Healthcare announced today the submission of a supplemental new drug application to the US FDA for ...

Read more →

Locate Bio’s Chondro3 granted FDA breakthrough device designation

24 February 2021 - The Company’s second FDA Breakthrough Device designation granted in 2021. ...

Read more →

EMA starts rolling review of Celltrion antibody regdanvimab for COVID-19

24 February 2021 - EMA’s CHMP has started a ‘rolling review’ of data on the monoclonal antibody regdanvimab (also known ...

Read more →

PHARMAC knew of epilepsy drug change risks within some patients, but went ahead with switch

24 February 2021 - PHARMAC knew there were clinical reasons some epilepsy patients would not tolerate a change to their medicines.  ...

Read more →

Antengene announces new drug application for ATG-010 (selinexor) granted priority review by China's NMPA

23 February 2021 - Antengene today announced that China's National Medical Products Administration has granted priority review to the new drug ...

Read more →

Health Canada approves Dupixent (dupilumab) as the first biologic for the treatment of moderate to severe atopic dermatitis in children aged 6 to 11 years

23 February 2021 - Dupixent is the only biologic medicine approved to treat atopic dermatitis for this patient population. ...

Read more →

U.S. FDA accepts for priority review Pfizer's application for Ticovac (tick-borne encephalitis vaccine)

23 February 2021 - If approved, the vaccine may help reduce the risk of tick-borne encephalitis for people traveling to endemic ...

Read more →

Inovise receives breakthrough device designation for novel non-invasive system to remotely monitor risk of decompensation in heart failure patients

23 February 2021 - Inovise Medical today announced the U.S. FDA has granted breakthrough device designation for its Audicor heart failure ...

Read more →

TGA bans Pfizer, AstraZeneca brand mentions in COVID-19 vaccine advertising

24 February 2021 - Pharmacies, GPs and healthcare organisations will be banned from displaying advertisements identifying whether they are using ...

Read more →